MARKET

APVO

APVO

Aptevo Therapeutics Inc
NASDAQ
1.100
+0.060
+5.77%
After Hours: 1.090 -0.01 -0.91% 19:51 12/16 EST
OPEN
1.000
PREV CLOSE
1.040
HIGH
1.110
LOW
1.000
VOLUME
673.17K
TURNOVER
--
52 WEEK HIGH
109.80
52 WEEK LOW
1.000
MARKET CAP
18.54M
P/E (TTM)
-0.0001
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at APVO last week (1208-1212)?
Weekly Report · 1d ago
Aptevo Therapeutics Announces Promising RAINIER Trial Results
TipRanks · 12/09 22:48
Aptevo Therapeutics presents preliminary results from Phase 1b/2 RAINIER study
TipRanks · 12/09 13:26
Aptevo Therapeutics Presents Preliminary Results From Ongoing Phase 1b/2 RAINIER Study Evaluating Mipletamig In Combination With AZA/VEN For Newly Diagnosed AML Patients, At ASH Annual Meeting
Benzinga · 12/09 13:12
Aptevo Therapeutics Reports Strong Remission Rates and Safety for Mipletamig in Frontline AML Trial
Reuters · 12/09 13:05
Weekly Report: what happened at APVO last week (1201-1205)?
Weekly Report · 12/08 09:15
Weekly Report: what happened at APVO last week (1124-1128)?
Weekly Report · 12/01 09:14
Weekly Report: what happened at APVO last week (1117-1121)?
Weekly Report · 11/24 09:15
More
About APVO
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.

Webull offers Aptevo Therapeutics Inc stock information, including NASDAQ: APVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APVO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APVO stock methods without spending real money on the virtual paper trading platform.